<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "2: from primarily research", fill: "#d2b48c"},
{source: "2: from primarily research", target: "2: development", fill: "#d2b48c"},
{source: "2: development", target: "2: applications", fill: "#d2b48c"},
{source: "2: applications", target: "2: oxygen implantation equipment", fill: "#d2b48c"},
{source: "2: from primarily research", target: "5: semiconductor", fill: "#da2c43"},
{source: "5: semiconductor", target: "5: manufacturers", fill: "#da2c43"},
{source: "5: manufacturers", target: "5: major silicon wafer", fill: "#da2c43"},
{source: "5: major silicon wafer", target: "5: technology would adversely affect", fill: "#da2c43"},
{source: "5: technology would adversely affect", target: "5: technology by others", fill: "#da2c43"},
{source: "5: semiconductor", target: "12: management", fill: "#78184a"},
{source: "12: management", target: "12: sufficient cash", fill: "#78184a"},
{source: "12: sufficient cash", target: "12: cash on hand", fill: "#78184a"},
{source: "12: cash on hand", target: "12: customer acceptance", fill: "#78184a"},
{source: "12: customer acceptance", target: "12: implanter which", fill: "#78184a"},
{source: "12: implanter which", target: "12: implanter shipped", fill: "#78184a"},
{source: "12: implanter shipped", target: "12: support current operations", fill: "#78184a"},
{source: "12: support current operations", target: "12: next twelve months", fill: "#78184a"},
{source: "12: management", target: "17: technology", fill: "#e49b0f"},
{source: "17: technology", target: "17: capabilities", fill: "#e49b0f"},
{source: "17: capabilities", target: "17: investment", fill: "#e49b0f"},
{source: "17: technology", target: "20: no assurance however", fill: "#00ff7f"},
{source: "20: no assurance however", target: "20: expectations", fill: "#00ff7f"},
{source: "20: expectations", target: "20: operations on", fill: "#00ff7f"},
{source: "20: no assurance however", target: "22: timely basis", fill: "#26619c"},
{source: "22: timely basis", target: "22: which would seriously harm", fill: "#26619c"},
{source: "22: which would seriously harm", target: "22: operations", fill: "#26619c"},
{source: "22: operations", target: "22: continue as", fill: "#26619c"},
{source: "22: timely basis", target: "23: raise additional funds through", fill: "#91a3b0"},
{source: "23: raise additional funds through", target: "23: convertible debt", fill: "#91a3b0"},
{source: "23: convertible debt", target: "23: common stock outstanding may", fill: "#91a3b0"},
{source: "23: raise additional funds through", target: "24: issue securities", fill: "#c90016"},
{source: "24: issue securities", target: "24: rights preferences", fill: "#c90016"},
{source: "24: rights preferences", target: "24: common stock", fill: "#c90016"},
{source: "24: issue securities", target: "28: significant decrease", fill: "#faebd7"},
{source: "28: significant decrease", target: "28: implanters", fill: "#faebd7"},
{source: "28: implanters", target: "28: customers which would", fill: "#faebd7"},
{source: "28: significant decrease", target: "32: manufacturing", fill: "#c71585"},
{source: "32: manufacturing", target: "32: qualification", fill: "#c71585"},
{source: "32: qualification", target: "32: each implanter", fill: "#c71585"},
{source: "32: each implanter", target: "32: customer qualify", fill: "#c71585"},
{source: "32: customer qualify", target: "32: premises disassemble", fill: "#c71585"},
{source: "32: premises disassemble", target: "32: transportation", fill: "#c71585"},
{source: "32: transportation", target: "32: customers premises", fill: "#c71585"},
{source: "32: manufacturing", target: "41: wafer manufacturing equipment from", fill: "#800080"},
{source: "41: wafer manufacturing equipment from", target: "41: significant customers", fill: "#800080"},
{source: "41: wafer manufacturing equipment from", target: "53: risk factors may also", fill: "#3f00ff"},
{source: "53: risk factors may also", target: "53: variations", fill: "#3f00ff"},
{source: "53: variations", target: "53: operations", fill: "#3f00ff"},
{source: "53: operations", target: "53: cancellations", fill: "#3f00ff"},
{source: "53: cancellations", target: "53: shipment delays", fill: "#3f00ff"},
{source: "53: shipment delays", target: "53: rescheduling", fill: "#3f00ff"},
{source: "53: rescheduling", target: "53: new product introductions which", fill: "#3f00ff"},
{source: "53: new product introductions which", target: "53: development expenses", fill: "#3f00ff"},
{source: "53: development expenses", target: "53: recognition", fill: "#3f00ff"},
{source: "53: recognition", target: "53: economic conditions", fill: "#3f00ff"},
{source: "53: economic conditions", target: "53: semiconductor industry", fill: "#3f00ff"},
{source: "53: semiconductor industry", target: "53: industries", fill: "#3f00ff"},
{source: "53: risk factors may also", target: "58: Competitors ", fill: "#979aaa"},
{source: "58: Competitors ", target: "101: entered into", fill: "#007fff"},
{source: "101: entered into", target: "101: employment agreement with", fill: "#007fff"},
{source: "101: employment agreement with", target: "101: Chief Executive Officer ", fill: "#007fff"},
{source: "101: Chief Executive Officer ", target: "101: under certain circumstances", fill: "#007fff"},
{source: "101: under certain circumstances", target: "101: employment with us", fill: "#007fff"},
{source: "101: entered into", target: "START_HERE", fill: "#007fff"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Semiconductors and Semiconductor Equipment</td>
    </tr>
    <tr>
      <td>Semiconductor Equipment</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
    <tr>
      <td>Construction and Engineering</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Automobiles and Components</td>
    </tr>
    <tr>
      <td>Electrical Components and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Grant</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Veto</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Consult</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dental_implant">Dental implant</a></td>
      <td>A dental implant (also known as an endosseous implant or fixture) is a prosthesis that interfaces with the bone of the jaw or skull to support a dental prosthesis such as a crown, bridge, denture, or facial prosthesis or to act as an orthodontic anchor. The basis for modern dental implants is a biologic process called osseointegration, in which materials such as titanium or zirconia form an intimate bond to bone.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Semiconductor_industry">Semiconductor industry</a></td>
      <td>The semiconductor industry is the aggregate of companies engaged in the design and fabrication of semiconductors and semiconductor devices, such as transistors and integrated circuits. It formed around 1960, once the fabrication of semiconductor devices became a viable business.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Fairchild_Semiconductor">Fairchild Semiconductor</a></td>
      <td>Fairchild Semiconductor International, Inc. was an American semiconductor company based in San Jose, California.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_aircraft_manufacturers">List of aircraft manufacturers</a></td>
      <td>This is a list of aircraft manufacturers sorted alphabetically by International Civil Aviation Organization (ICAO)/common name. It contains the ICAO/common name, manufacturers name(s), country and other data, with the known years of operation in parentheses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_modern_armament_manufacturers">List of modern armament manufacturers</a></td>
      <td>The following list of modern armament manufacturers presents major companies producing modern weapons and munitions for military, paramilitary, government agency and civilian use. The companies are listed by their full name followed by the short form, or common acronym, if any, in parentheses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_loudspeaker_manufacturers">List of loudspeaker manufacturers</a></td>
      <td>This is a list of notable manufacturers of loudspeakers. In regard to notability, this is not intended to be an all-inclusive list; it is a list of manufacturers especially noted for their loudspeakers and which have articles on Wikipedia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_computer_hardware_manufacturers">List of computer hardware manufacturers</a></td>
      <td>Current notable computer hardware manufacturers:\n\n\n== Cases ==\nList of computer case manufacturers:\n\n\n=== Rack-mount computer cases ===\n\n\n== Laptop computer cases ==\nClevo\nMSI\n\n\n== Motherboards ==\nTop motherboard manufacturers:\n\nList of motherboard manufacturers:\n\nDefunct:\n\n\n== Chipsets for motherboards ==\n\n\n== Central processing units (CPUs) ==\nNote: most of these companies only make designs, and do not manufacture their own designs. \nTop x86 CPU manufacturers:\n\nList of CPU manufacturers (most of the companies sell ARM-based CPUs, assumed if nothing else stated):\n\nAcquired or defunct:\n\n\n== Hard disk drives (HDDs) ==\n\n\n=== Internal ===\nList of current hard disk drive manufacturers:\n\nSeagate Technology\nToshiba\nWestern Digital\n\n\n=== External ===\nNote: the HDDs internal to these devices are manufactured only by the internal HDD manufacturers listed above.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Original_equipment_manufacturer">Original equipment manufacturer</a></td>
      <td>An original equipment manufacturer (OEM) is generally perceived as a company that produces parts and equipment that may be marketed by another manufacturer.\nHowever, the term is also used in several other ways, which causes ambiguity.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturers_Hanover_Corporation">Manufacturers Hanover Corporation</a></td>
      <td>Manufacturers Hanover Corporation  was the bank holding company formed as parent of Manufacturers Hanover Trust Company, a large New York bank formed by a merger in 1961.  After 1969, Manufacturers Hanover Trust became a subsidiary of Manufacturers Hanover Corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Customer_to_customer">Customer to customer</a></td>
      <td>Customer to customer (C2C or consumer to consumer) markets provide a way to allow customers to interact with each other.  Traditional markets require business to customer relationships, in which a customer goes to the business in order to purchase a product or service.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Brain_implant">Brain implant</a></td>
      <td>Brain implants, often referred to as neural implants, are technological devices that connect directly to a biological subject's brain – usually placed on the surface of the brain, or attached to the brain's cortex. A common purpose of modern brain implants and the focus of much current research is establishing a biomedical prosthesis circumventing areas in the brain that have become dysfunctional after a stroke or other head injuries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Breast_implant">Breast implant</a></td>
      <td>A breast implant is a prosthesis used to change the size, shape, and contour of a person's breast. In reconstructive plastic surgery, breast implants can be placed to restore a natural looking breast following a mastectomy, to correct congenital defects and deformities of the chest wall or, cosmetically, to enlarge the appearance of the breast through breast augmentation surgery.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Cochlear_implant">Cochlear implant</a></td>
      <td>A cochlear implant (CI) is a surgically implanted neuroprosthesis that provides a person who has moderate-to-profound sensorineural hearing loss with sound perception. With the help of therapy, cochlear implants may allow for improved speech understanding in both quiet and noisy environments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Educational_technology">Educational technology</a></td>
      <td>Educational technology (commonly abbreviated as edutech, or edtech) is the combined use of computer hardware, software, and educational theory and practice to facilitate learning. When referred to with its abbreviation, edtech, it is often referring to the industry of companies that create educational technology.In addition to practical educational experience, educational technology is based on theoretical knowledge from various disciplines such as communication, education, psychology, sociology, artificial intelligence, and computer science.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology_company">Technology company</a></td>
      <td>A technology company (or tech company) is an electronics-based technological company, including, for example, business relating to digital electronics, software, and internet-related services, such as e-commerce services.\n\n\n== Details ==\nAccording to Fortune, as of 2020, the ten largest technology companies by revenue are: Apple Inc., Samsung, Foxconn, Alphabet Inc., Microsoft, Huawei, Dell Technologies, Hitachi, IBM, and Sony.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arithmetic">Arithmetic</a></td>
      <td>Arithmetic (from Ancient Greek  ἀριθμός (arithmós) 'number', and  τική [τέχνη] (tikḗ [tékhnē]) 'art, craft') is an elementary part of mathematics that consists of the study of the properties of the traditional operations on numbers—addition, subtraction, multiplication, division, exponentiation, and extraction of roots. In the 19th century, Italian mathematician Giuseppe Peano formalized arithmetic with his Peano axioms, which are highly important to the field of mathematical logic today.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operations_management">Operations management</a></td>
      <td>Operations management is an area of management concerned with designing and controlling the process of production and redesigning business operations in the production of goods or services. It involves the responsibility of ensuring that business operations are efficient in terms of using as few resources as needed and effective in meeting customer requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Implant">Implant</a></td>
      <td>Plants are predominantly photosynthetic eukaryotes of the kingdom Plantae. Historically, the plant kingdom encompassed all living things that were not animals, and included algae and fungi; however, all current definitions of Plantae exclude the fungi and some algae, as well as the prokaryotes (the archaea and bacteria).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_Consent">Manufacturing Consent</a></td>
      <td>Manufacturing Consent: The Political Economy of the Mass Media is a 1988 book by Edward S. Herman and Noam Chomsky. It argues that the mass communication media of the U.S. "are effective and powerful ideological institutions that carry out a system-supportive propaganda function, by reliance on market forces, internalized assumptions, and self-censorship, and without overt coercion", by means of the propaganda model of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Textile_manufacturing">Textile manufacturing</a></td>
      <td>Textile manufacturing is a major industry. It is largely based on the conversion of fibre into yarn, then yarn into fabric.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_engineering">Manufacturing engineering</a></td>
      <td>Manufacturing engineering is a branch of professional engineering that shares many common concepts and ideas with other fields of engineering such as mechanical, chemical, electrical, and industrial engineering. \nManufacturing engineering requires the ability to plan the practices of manufacturing; to research and to develop tools, processes, machines and equipment; and to integrate the facilities and systems for producing quality products with the optimum expenditure of capital.The manufacturing or production engineer's primary focus is to turn raw material into an updated or new product in the most effective, efficient &amp; economic way possible.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing_cost">Manufacturing cost</a></td>
      <td>Manufacturing cost is the sum of costs of all resources consumed in the process of making a product. The manufacturing cost is classified into three categories: direct materials cost, direct labor cost and manufacturing overhead.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Murata_Manufacturing">Murata Manufacturing</a></td>
      <td>Murata Manufacturing Co., Ltd. (株式会社村田製作所, Kabushiki-gaisha Murata Seisakusho) is a Japanese manufacturer of electronic components, based in Nagaokakyo, Kyoto.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Tire_manufacturing">Tire manufacturing</a></td>
      <td>Pneumatic tires are manufactured according to relatively standardized processes and machinery, in around 455 tire factories in the world. With over 1 billion tires manufactured worldwide annually, the tire industry is a major consumer of natural rubber.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Semiconductor_fabrication_plant">Semiconductor fabrication plant</a></td>
      <td>In the microelectronics industry, a semiconductor fabrication plant (commonly called a fab; sometimes foundry) is a factory where devices such as integrated circuits are manufactured.Fabs require many expensive devices to function. Estimates put the cost of building a new fab over one billion U.S. dollars with values as high as $3–4 billion not being uncommon.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Semiconductor_industry_in_Taiwan">Semiconductor industry in Taiwan</a></td>
      <td>The Taiwanese semiconductor industry, including IC manufacturing, design, and packing, forms a major part of Taiwan's IT industry. Due to its strong capabilities in OEM wafer manufacturing and a complete industry supply chain, Taiwan has been able to distinguish itself from its competitors and dominate the global marketplace.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Electronics_and_semiconductor_manufacturing_industry_in_India">Electronics and semiconductor manufacturing industry in India</a></td>
      <td>The Indian electronics industry saw growth in the early years of the 21st century, encouraged both by government policies and incentives and by international investment. Its key and most resource-intensive segment, the semiconductor industry benefitted from domestic demand growing briskly.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Electronics_industry">Electronics industry</a></td>
      <td>The electronics industry is the economic sector that produces electronic devices. It emerged in the 20th century and is today one of the largest global industries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chief_executive_officer">Chief executive officer</a></td>
      <td>A chief executive officer (CEO), chief administrator officer (CAO), central executive officer (CEO), or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization –  especially an independent legal entity such as a company or nonprofit institution. CEOs find roles in a range of organizations, including public and private corporations, non-profit organizations and even some government organizations (notably state-owned enterprises).</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>IBIS TECHNOLOGY CORP      Item 1A  RISK FACTORS         The Commercial Market for SIMOX-SOI Technology is <font color="blue">Still Developing </font>and     <font color="blue">May Never Fully Develop</font></td>
    </tr>
    <tr>
      <td>The  sources  of  our revenue have shifted <font color="blue">from primarily research</font> and     <font color="blue">development</font>  contracts  and  sales  of SIMOX-SOI wafers for commercial     <font color="blue"><font color="blue">application</font>s</font> to sales and support of <font color="blue"><font color="blue">oxygen implantation</font> equipment</font></td>
    </tr>
    <tr>
      <td>We are     aware of only a <font color="blue">few commercial <font color="blue"><font color="blue">manufacture</font>rs</font></font> that are using SIMOX-SOI wafers     in <font color="blue">low volume production</font> for a limited number of products</td>
    </tr>
    <tr>
      <td>The performance     <font color="blue">advantages</font> of SIMOX-SOI <font color="blue">wafers may never</font> be realized <font color="blue">commercially</font> and a     <font color="blue">commercial market</font> for SIMOX-SOI <font color="blue">wafers may never</font> fully develop which in                                           11     ______________________________________________________________________         turn <font color="blue">would <font color="blue">adversely</font> affect</font> the sales of our <font color="blue">oxygen <font color="blue">implanters</font></font></td>
    </tr>
    <tr>
      <td>The failure     of  major  <font color="blue">semiconductor</font>  <font color="blue"><font color="blue">manufacture</font>rs</font>  and  /or  <font color="blue">major silicon wafer</font>     <font color="blue"><font color="blue">manufacture</font>rs</font> to adopt SIMOX-SOI <font color="blue">technology</font> <font color="blue">would <font color="blue">adversely</font> affect</font>, and may     prevent, the adoption of this <font color="blue"><font color="blue">technology</font> by others</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">December </font></font>31, 2005, we had an     <font color="blue">accumulated</font>  deficit of dlra82dtta0 million</td>
    </tr>
    <tr>
      <td>Net <font color="blue">losses may continue</font> for the     <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>Although we have had <font color="blue">profitable quarterly</font> operating     results  from  time  to  time, we may not be able to achieve sustained     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>The  Company’s  <font color="blue">management</font>  believes that it will have <font color="blue">sufficient cash</font>     resources including the <font color="blue">cash on hand</font> expected to be received from final     <font color="blue">customer <font color="blue">acceptance</font></font> <font color="blue">of the SUMCO </font><font color="blue">implanter which</font> was received in March 2006     for the <font color="blue">implanter shipped</font> in June 2005 to <font color="blue"><font color="blue">support current</font> <font color="blue">operations</font></font> for the     <font color="blue">next twelve months</font></td>
    </tr>
    <tr>
      <td>With the receipt of the order received from SUMCO in     October 2005, which the Company believes it can <font color="blue">ship during</font> the second     quarter of 2006, and presuming that <font color="blue">customer <font color="blue">acceptance</font></font> and full payment of     that order occurs during 2006, the Company believes it will have sufficient     cash to <font color="blue">support current</font> operating <font color="blue">levels through at least</font> the <font color="blue">next eighteen</font>     <font color="blue">months from</font> the date of this filing</td>
    </tr>
    <tr>
      <td>However, this <font color="blue">expectation</font> is <font color="blue">based on</font>     our current operating plan and general sales outlook, each of which may     change rapidly</td>
    </tr>
    <tr>
      <td>We intend to continue to invest in our research, <font color="blue">development</font>     and <font color="blue"><font color="blue">manufacturing</font> <font color="blue">capabilities</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>expects to continue to explore     <font color="blue">equity offerings</font> and other forms of financing and anticipate that we may be     required to <font color="blue">raise <font color="blue">additional</font> capital</font> in the future in order to finance     future  growth  and  our research and <font color="blue">development</font> programs</td>
    </tr>
    <tr>
      <td>Changes in     <font color="blue">technology</font> or sales growth beyond currently established <font color="blue">capabilities</font> may     require further <font color="blue">investment</font></td>
    </tr>
    <tr>
      <td>As a result, we may need to raise substantial     <font color="blue">additional</font> capital in the future</td>
    </tr>
    <tr>
      <td>We have <font color="blue">previously financed</font> our working     <font color="blue">capital <font color="blue">requirements</font> through</font>:         •                <font color="blue">equity financings</font>, including warrant and <font color="blue">option exercises</font>,       •                <font color="blue">equipment lines</font> of credit,       •                a working <font color="blue">capital line</font> of credit,       •                a term loan,       •                sale-leaseback arrangements,       •                <font color="blue">collaborative <font color="blue">relationships</font></font>,       •                <font color="blue">wafer product</font> and <font color="blue">equipment sales</font>, and       •                <font color="blue">government contracts</font></td>
    </tr>
    <tr>
      <td>There can be no assurance, however, that our actual needs will not exceed     <font color="blue">expectation</font>s or that we will be able to fund our <font color="blue"><font color="blue">operations</font> on</font> a long-term     basis in the absence of other sources</td>
    </tr>
    <tr>
      <td>There also can be no assurance that     any <font color="blue">additional</font> required <font color="blue">longer term financing will</font> be available through     <font color="blue">additional</font> bank borrowings, debt or <font color="blue">equity offerings</font> or otherwise, or that     if  such  financing  is  available, that it will be <font color="blue">available on terms</font>     acceptable to us</td>
    </tr>
    <tr>
      <td>If future financing is not available or is not available     on a <font color="blue">timely basis</font> or on acceptable terms, we may not be able to fund our     future  needs,  <font color="blue">which would seriously harm</font> our business and results of     <font color="blue">operations</font> and our ability to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>In addition, if     we raise <font color="blue">additional</font> funds through the sale of equity or <font color="blue">convertible debt</font>     securities, the value of our <font color="blue"><font color="blue">common stock</font> outstanding may</font> be diluted</td>
    </tr>
    <tr>
      <td>We may     also have to <font color="blue">issue securities</font> that have rights, preferences and privileges     senior to our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Currently, We Rely on <font color="blue">Sales to a Limited Number of Customers</font></td>
    </tr>
    <tr>
      <td>Ibis expects that we <font color="blue">will continue</font> to rely on a <font color="blue">relatively</font> small number of     <font color="blue">customers as sources</font> of revenue in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>The loss of one     or more of these <font color="blue">major customers</font> and our failure to obtain other sources of     <font color="blue">offsetting revenue would</font> have a material <font color="blue"><font color="blue">adverse impact</font> on</font> our business and     hinder our ability to <font color="blue">continue as</font> a going concern</td>
    </tr>
    <tr>
      <td>In addition, any downturn     in these customers’ business or the industry                                             12     ______________________________________________________________________         in which these customers operate could result in a <font color="blue"><font color="blue">significant</font> decrease</font> in     any sales of our <font color="blue">implanters</font> to these customers, which would have an adverse     effect on our business</td>
    </tr>
    <tr>
      <td>Revenue  Recognition  and  Cash  Payments  from  <font color="blue">Customers Depend </font>on a     Manufacturing and Customer Qualification and Acceptance Process that is     Complex, Lengthy and Costly</td>
    </tr>
    <tr>
      <td>In  the  <font color="blue">semiconductor</font>  industry customers regularly require equipment     <font color="blue"><font color="blue">manufacture</font>rs</font> to qualify the equipment at the customer’s site</td>
    </tr>
    <tr>
      <td>The time     required to customer-qualify an <font color="blue">implanter at</font> a customer’s site is very     <font color="blue">difficult</font> to predict because the <font color="blue"><font color="blue">qualification</font> process</font> for each of our     <font color="blue">implanters</font>  is complex, lengthy and costly and <font color="blue">varies depending on</font> the     customer’s varying <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">manufacturing</font> and <font color="blue">qualification</font>     process for <font color="blue">each implanter</font> requires us to construct and <font color="blue">customer qualify</font> the     machine at our premises, disassemble the machine for <font color="blue">transportation</font>, and     reassemble  and  re-qualify it at the customer’s premises</td>
    </tr>
    <tr>
      <td>During this     <font color="blue">qualification</font>  period,  we  invest  <font color="blue"><font color="blue">significant</font> resources</font> and dedicate     substantial production and <font color="blue">technical personnel</font> to achieve <font color="blue">acceptance</font> of the     implanter</td>
    </tr>
    <tr>
      <td>A  customer  will  not  accept  the <font color="blue">implanter until</font> it has     <font color="blue">successfully</font> produced wafers to exact <font color="blue"><font color="blue">specifications</font> at</font> the customer’s     premises</td>
    </tr>
    <tr>
      <td>Even very small <font color="blue">differences</font> in the customer’s environment or     <font color="blue">initially imperceptible</font> changes that may occur to the implanter during the     <font color="blue">transportation</font> to and <font color="blue">reassembly</font> of the <font color="blue">implanter at</font> the customer’s site can     cause a large percentage of wafers produced by the implanter to be rejected,     which  would  delay  the  <font color="blue">acceptance</font> of the <font color="blue">implanter by</font> the customer</td>
    </tr>
    <tr>
      <td>Historically, we have experienced delays in achieving <font color="blue">customer <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>Delays or <font color="blue">difficult</font>ies in our <font color="blue">manufacturing</font> and <font color="blue"><font color="blue">qualification</font> process</font> could     increase  <font color="blue">manufacturing</font>  and  warranty  costs and <font color="blue">adversely</font> affect our     <font color="blue">relationships</font> with our customers</td>
    </tr>
    <tr>
      <td>In addition, because we do not recognize     <font color="blue">revenue on</font> the sale of an <font color="blue">implanter until</font> it is delivered and <font color="blue">qualified by</font>     the customer, any delay in <font color="blue">qualification</font> would result in a delay in our     ability to recognize <font color="blue">revenue from</font> the sale and receipt of <font color="blue">final payment</font></td>
    </tr>
    <tr>
      <td><font color="blue">Historically </font>it has <font color="blue">taken <font color="blue">approximately</font> nine</font> to eighteen <font color="blue">months from</font> our     receipt of our order to build, ship and obtain <font color="blue">customer <font color="blue">acceptance</font></font> of our     <font color="blue">implanters</font></td>
    </tr>
    <tr>
      <td><font color="blue">We Rely Heavily </font>on Sales to a Small Number of Significant Customers, Which     May Cause Sales to Vary Significantly from Quarter to Quarter Causing Our     Operating Results to Fluctuate</td>
    </tr>
    <tr>
      <td>We derive a large portion of our sales of wafer <font color="blue">manufacturing</font> equipment from     a small number of <font color="blue"><font color="blue">significant</font> customers</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">following table sets forth</font>, in     thousands of dollars, the amount of <font color="blue">revenue derived from</font> our <font color="blue">significant</font>     <font color="blue">customers during</font> the <font color="blue">fiscal years</font> ended <font color="blue">December </font>31, 2003, 2004 and 2005, as     well as the percent of our <font color="blue">revenue represented by</font> these customers’ purchases     (in thousands):                                                          2003                                                2004                                                2005               Customer                                              Dollars                                              Percent                                              Dollars                                              Percent                                              Dollars                                              Percent               IBM         $                                                                        8cmam564         91       %       $                                                                          384         5       %       $                                                                           74         12       %       Simgui         $                                                                          526         6       %       $                                                                            5         —         —         —         SEH         —         —         $                                                                        7cmam000         88       %                                                                            —         —         Nissin Electric         —         —         —         —         $                                                                          279         46       %       Tokyo Iovenus         —         —         —         —         $                                                                          162         27       %         Revenue from IBM in 2005 is for service and parts</td>
    </tr>
    <tr>
      <td>The <font color="blue">revenue from</font> <font color="blue">Nissin     </font>in 2005 was from license royalties and the <font color="blue">revenue from</font> Tokyo Iovenus in     2005 was from the sale of parts</td>
    </tr>
    <tr>
      <td>Revenues from Simgui in 2003     represent the sale of license <font color="blue">technology</font> and certain parts</td>
    </tr>
    <tr>
      <td>We anticipate that our revenue and operating results are likely to vary     <font color="blue">significant</font>ly from quarter to quarter in the <font color="blue">foreseeable future</font>, and it is     likely that in <font color="blue">future quarters</font> our operating results may from time to time     be below the <font color="blue">expectation</font>s of <font color="blue"><font color="blue">public market</font> analysts</font> or investors</td>
    </tr>
    <tr>
      <td>Our stock     price has <font color="blue">been volatile</font> and if we fail to meet <font color="blue">expectation</font>s of <font color="blue">public market</font>     analysts or investors, the price of our <font color="blue">common stock</font> would likely                                           13     ______________________________________________________________________         decrease</td>
    </tr>
    <tr>
      <td>Further, <font color="blue">customers may cancel</font> or <font color="blue">revise orders at</font> any time prior     to delivery</td>
    </tr>
    <tr>
      <td>These <font color="blue">ordering patterns most likely will</font> result in <font color="blue">significant</font>     <font color="blue">quarterly <font color="blue">fluctuations</font></font> in our revenue and operating results, and <font color="blue">accordingly</font>     in our share price</td>
    </tr>
    <tr>
      <td>In addition, because we have only sold a limited number     of <font color="blue">implanters</font> to date on an <font color="blue">irregular basis</font>, the <font color="blue">recognition</font> of <font color="blue">revenue from</font>     the sale of <font color="blue">even one implanter</font> is likely to result in a <font color="blue">significant</font> increase     in the revenue for that quarter</td>
    </tr>
    <tr>
      <td>A number of other factors, many of which     are  discussed  in  more  detail in other risk factors, may also cause     <font color="blue">variations</font> in our results of <font color="blue">operations</font> and share price, including:         •                                          lack of orders,       •                                          <font color="blue"><font color="blue">cancellation</font>s</font> of orders and     <font color="blue">shipment delays</font> and <font color="blue">rescheduling</font>,       •                                          new <font color="blue">product introductions</font>, which     often result in a mismatching of research and <font color="blue">development</font> expenses and     <font color="blue">recognition</font> of revenue, and       •                                          <font color="blue">economic <font color="blue">conditions</font></font> and capital     spending in the <font color="blue">semiconductor</font> industry and in other <font color="blue">industries</font> in which our     customers operate</td>
    </tr>
    <tr>
      <td>A <font color="blue">high percentage</font> of our expenses are <font color="blue">essentially</font> fixed in the short term</td>
    </tr>
    <tr>
      <td>As a result, if we experience delays in <font color="blue">generating</font> and recognizing revenue,     our quarterly operating results are likely to be seriously harmed</td>
    </tr>
    <tr>
      <td>Due to     this, as well as to the <font color="blue">cyclicality</font> of the <font color="blue">semiconductor</font> industry and other     factors, we believe that quarter-to-quarter comparisons of our operating     results will not be <font color="blue">meaningful</font></td>
    </tr>
    <tr>
      <td>You should not rely on our results for one     <font color="blue">quarter as</font> any <font color="blue">indication</font> of our <font color="blue">future performance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Competitors  </font>and  Competing Technologies May Render Some or All of Our     Products or Future Products Noncompetitive or Obsolete; Potential Write-down     for Impaired or Obsolete Assets</td>
    </tr>
    <tr>
      <td>The <font color="blue">semiconductor</font> industry is <font color="blue">highly competitive</font> and has <font color="blue">been characterized</font>     by rapid and <font color="blue">significant</font> <font color="blue">technological</font> advances</td>
    </tr>
    <tr>
      <td>A number of established     <font color="blue">semiconductor</font>  and  materials  <font color="blue"><font color="blue">manufacture</font>rs</font>, including certain of our     customers, have expended <font color="blue"><font color="blue">significant</font> resources</font> in developing <font color="blue">improved wafer</font>     substrates</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> or others, many of which have <font color="blue">substantially</font>     greater financial, technical and other <font color="blue">resources than</font> we do, may succeed in     developing <font color="blue">technologies</font> and products that are equal to or more <font color="blue">effective</font>     than any which we are developing, <font color="blue">which could</font> render our <font color="blue">technology</font> obsolete     or <font color="blue">noncompetitive</font></td>
    </tr>
    <tr>
      <td>In addition to <font color="blue">competition from</font> other <font color="blue"><font color="blue">manufacture</font>rs</font> of     SOI wafers, we face <font color="blue">competition from</font> <font color="blue"><font color="blue">manufacture</font>rs</font> using bulk silicon and     epitaxial  wafer <font color="blue">technology</font>, and compound materials <font color="blue">technology</font> such as     silicon-germanium, gallium-arsenide and <font color="blue">indium phosphide</font> and SOI <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  believe  that  SIMOX-SOI <font color="blue">wafers offer integrated circuit</font>     performance <font color="blue">advantages</font>, <font color="blue">semiconductor</font> <font color="blue"><font color="blue">manufacture</font>rs</font> may develop <font color="blue">improvements</font>     to existing bulk silicon, epitaxial or strained silicon wafer <font color="blue">technology</font>,     and  competing  compound  materials  or  SOI  <font color="blue">technologies</font> may be more     <font color="blue">successfully</font> developed, <font color="blue">which would eliminate</font> or diminish the performance     <font color="blue">advantages</font> of SIMOX-SOI <font color="blue">wafers which</font> in turn <font color="blue">would diminish</font> the demand for     our <font color="blue">oxygen <font color="blue">implanters</font></font></td>
    </tr>
    <tr>
      <td>Further, in addition to the SIMOX implanter other     <font color="blue">equipment must</font> be purchased and implemented in order to complete the <font color="blue">SIMOX     </font>wafer <font color="blue">manufacturing</font> process</td>
    </tr>
    <tr>
      <td>During the fiscal year ended <font color="blue">December </font>31, 2004, we <font color="blue">discontinued</font> our wafer     <font color="blue">manufacturing</font> business and <font color="blue">incurred charges</font> for severance and equipment     <font color="blue">disposition</font> of dlra2dtta1 million, contributing to the loss from <font color="blue">discontinued</font>     <font color="blue">operations</font> of dlra5dtta3 million</td>
    </tr>
    <tr>
      <td>During the fiscal year ended <font color="blue">December </font>31, 2003,     we recognized an <font color="blue">impairment loss</font> of dlra11dtta1 million for our 200 mm and smaller     SIMOX <font color="blue">wafer product</font>ion line which has <font color="blue">subsequently been recorded as</font> part of     the loss from <font color="blue">discontinued</font> <font color="blue">operations</font> in 2003 of dlra17dtta6 million</td>
    </tr>
    <tr>
      <td>In addition, if <font color="blue">semiconductor</font> <font color="blue"><font color="blue">manufacture</font>rs</font> fail to adopt <font color="blue">SIMOX     </font><font color="blue">technology</font> during the current or subsequent process cycle (such cycles     <font color="blue">typically last two</font> to three years), widespread adoption of SIMOX <font color="blue">technology</font>     may never materialize, our <font color="blue">technology</font> may become obsolete and we may be     required to recognize an <font color="blue">additional</font> material <font color="blue">impairment loss</font> in the future</td>
    </tr>
    <tr>
      <td>In addition, although we are aware of no other company <font color="blue">manufacturing</font> oxygen     <font color="blue">implant equipment</font>, other major <font color="blue">semiconductor</font> <font color="blue">implant equipment</font> <font color="blue"><font color="blue">manufacture</font>rs</font>     could develop a <font color="blue">less expensive oxygen implanter with</font> superior <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">compete with</font> other <font color="blue"><font color="blue">manufacture</font>rs</font> of <font color="blue">semiconductor</font> <font color="blue">implanters</font>,                                           14     ______________________________________________________________________         <font color="blue"><font color="blue">manufacture</font>rs</font>  of  competing SOI wafers, as well as with bulk silicon,     epitaxial, strained silicon and compound materials wafer <font color="blue"><font color="blue">manufacture</font>rs</font>, will     <font color="blue">depend on numerous factors within</font> and outside our control, including:         •                the success and timing of our <font color="blue">product introductions</font> and     those of our <font color="blue"><font color="blue">competitor</font>s</font>,       •                <font color="blue">product <font color="blue">distribution</font></font>,       •                <font color="blue">customer support</font>,       •                <font color="blue">sufficiency</font> of <font color="blue">funding available</font> to us, and       •                the price, quality and performance of <font color="blue">competing products</font>     and <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">semiconductor</font> industry is <font color="blue">characterized by rapid <font color="blue">technological</font></font> change,     <font color="blue">evolving industry standards</font> and continuous <font color="blue">improvements</font> in products and     required  customer  <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Due to the constant changes in our     markets,  our  future  success  depends  on our ability to improve our     <font color="blue">manufacturing</font> processes, improve existing products and develop <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>For example, our <font color="blue">oxygen <font color="blue">implanters</font></font> must <font color="blue">remain competitive</font> on the basis of     cost of ownership, process performance and <font color="blue">evolving customer</font> needs</td>
    </tr>
    <tr>
      <td>To     <font color="blue">remain competitive</font> we must continually introduce <font color="blue">oxygen <font color="blue">implanters</font></font> with     higher <font color="blue">capacity</font>, better production yields and the ability to <font color="blue">process larger</font>     <font color="blue">wafer sizes</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">commercialization</font> of <font color="blue">new products</font> involves, among other <font color="blue">requirements</font>,     substantial  <font color="blue">expenditures</font>  in research and <font color="blue">development</font>, production and     marketing</td>
    </tr>
    <tr>
      <td>We may be unable to <font color="blue">successfully</font> design or <font color="blue">manufacture</font> these new     products and may have <font color="blue">difficult</font>y penetrating new markets</td>
    </tr>
    <tr>
      <td>Because it is     <font color="blue">generally</font> not possible to predict the amount of time required and the costs     involved  in  achieving  certain research, <font color="blue">development</font> and <font color="blue">engineering</font>     <font color="blue">objectives</font>,  actual  <font color="blue">development</font> costs may exceed budgeted amounts and     estimated product <font color="blue">development</font> schedules may be extended</td>
    </tr>
    <tr>
      <td>Our business may be     <font color="blue">materially</font> and <font color="blue">adversely</font> affected if:         •                we are unable to improve our <font color="blue">existing products on</font> a timely     basis,       •                our <font color="blue">new products</font> are not <font color="blue">introduced on</font> a <font color="blue">timely basis</font>,       •                we <font color="blue">incur budget overruns</font> or delays in our research and     <font color="blue">development</font> efforts, or       •                 our  new  products experience <font color="blue">reliability</font> or quality     problems</td>
    </tr>
    <tr>
      <td><font color="blue">The Sales Cycle for Our Oxygen Implanter Equipment </font>is Lengthy and Complex     and We Have Only Received Limited Orders for Our Oxygen Implanter Equipment</td>
    </tr>
    <tr>
      <td>Our customers expend <font color="blue">significant</font> efforts in evaluating and qualifying our     <font color="blue">implanters</font>  before  they place <font color="blue">orders with us</font></td>
    </tr>
    <tr>
      <td>Since we <font color="blue">began selling</font>     <font color="blue">implanters</font> in 1996, we have only sold a total of eight Ibis 1000 oxygen     <font color="blue">implanters</font> at an <font color="blue">average sale price</font> of <font color="blue">approximately</font> dlra4dtta0 million each and     four i2000 <font color="blue">oxygen <font color="blue">implanters</font></font> (including the order received in October 2005)     at a selling price between dlra6dtta0 and dlra8dtta0 million</td>
    </tr>
    <tr>
      <td>The <font color="blue">sales cycle typically</font>     goes from equipment demonstration, equipment specification negotiations,     formal quotation, contract negotiations and receipt of order and could take     up to one year or longer</td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">potential equipment customers</font>     that  would  like to use the MLD process, owned by IBM, to <font color="blue">manufacture</font>     SIMOX-SOI <font color="blue">wafers using</font> our <font color="blue">implanters</font> would be required to license this     <font color="blue">technology</font> directly from IBM We believe two silicon wafer <font color="blue"><font color="blue">manufacture</font>rs</font>     have <font color="blue">already licensed</font> this <font color="blue">technology</font> from IBM and others have developed     their own SIMOX processes</td>
    </tr>
    <tr>
      <td>Our <font color="blue">potential equipment customers</font> may wish to     secure this <font color="blue">license prior</font> to <font color="blue">giving us</font> an order for equipment and these     <font color="blue">negotiations between</font> IBM and our customer are beyond our control and no     assurances  are  given  that our customers and IBM would come to terms     acceptable to <font color="blue">both parties</font> in a <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td><font color="blue">These MLD </font>process     license issues may effect the timing of placement of <font color="blue">customer orders</font> in the     future if customers plan to license this <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We do not expect to     sell more than a limited number of <font color="blue">implanters</font> in the near future</td>
    </tr>
    <tr>
      <td>The sale     of one implanter would <font color="blue">generally</font> represent a substantial portion of our     <font color="blue">annual revenue</font></td>
    </tr>
    <tr>
      <td>Accordingly, the delay in the receipt of orders, <font color="blue">manufacture</font>     or delivery of even one unit or the                                           15     ______________________________________________________________________         <font color="blue">modification</font>, change or <font color="blue">cancellation</font> of any such order would have a material     adverse effect on our quarterly and annual results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Implanters and Associated Technology </font>are Subject to Export Regulations,     Which Could Prevent or Delay the Sale of Such Products in Foreign Countries</td>
    </tr>
    <tr>
      <td>Certain <font color="blue">technologies</font> associated with our <font color="blue">implanters</font> are subject to export     <font color="blue"><font color="blue">regulations</font> administered by</font> the <font color="blue">US Department of Commerce</font></td>
    </tr>
    <tr>
      <td>Accordingly, we     may be required to secure US <font color="blue">export licenses with respect</font> to sales of     <font color="blue">implanters</font> or transfers of <font color="blue">technologies</font> to end users in <font color="blue">certain foreign</font>     countries</td>
    </tr>
    <tr>
      <td>This <font color="blue">requirement could</font> result in <font color="blue">significant</font> delays in, or the     prevention of, sales of <font color="blue">implanters</font> or transfers of <font color="blue">technology</font> or other such     <font color="blue">technical data</font> to customers in <font color="blue">certain foreign</font> countries</td>
    </tr>
    <tr>
      <td>For example, the     sale of an Ibis 1000 implanter and the <font color="blue">corresponding transfer</font> of <font color="blue">technology</font>     to Simgui required an <font color="blue">export license which</font> took <font color="blue"><font color="blue">approximately</font> one year</font> to     secure</td>
    </tr>
    <tr>
      <td>There can be no assurance that if <font color="blue">necessary</font>, we will be able to     <font color="blue">secure such licenses</font> in the future in a <font color="blue">timely manner</font>, or at all</td>
    </tr>
    <tr>
      <td>Our Chief Executive Officer, Martin J Reid, our Executive Vice President,     and Chief Operating Officer, Charles McKenna and other <font color="blue">current officers</font> and     key  members of our <font color="blue">scientific staff</font> are responsible for <font color="blue">areas such as</font>     product <font color="blue">development</font> and <font color="blue">improvements</font>, and process <font color="blue">improvements</font> research,     which are important to our <font color="blue">specialized scientific</font> business</td>
    </tr>
    <tr>
      <td>The loss of, and     failure to <font color="blue">promptly replace</font>, any member of this group could <font color="blue">significant</font>ly     delay and <font color="blue">may prevent</font> the <font color="blue">achievement</font> of our research, <font color="blue">development</font> and     business <font color="blue">objectives</font></td>
    </tr>
    <tr>
      <td>While we have <font color="blue">entered into</font> an <font color="blue">employment agreement with</font>     our Chief Executive Officer, <font color="blue">under certain circumstances</font> he may be able to     terminate his <font color="blue">employment with us</font></td>
    </tr>
    <tr>
      <td>Furthermore, although our employees are     subject to <font color="blue">certain confidentiality</font> and non-competition obligations, our key     <font color="blue">personnel may terminate</font> their <font color="blue">employment at</font> any time and <font color="blue">may become employed</font>     by a <font color="blue">competitor</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">current composition</font> of Ibis <font color="blue">management</font> and of its board     of <font color="blue">directors</font> is subject to change and should not be <font color="blue">unduly relied upon</font></td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>2004, the <font color="blue">Financial Accounting Standards Board </font>issued FASB     Statement Nodtta 123R, Share Based Payment, which requires all companies to     treat the <font color="blue">fair value</font> of <font color="blue"><font color="blue">stock options</font> granted</font> to <font color="blue">employees as</font> an expense</td>
    </tr>
    <tr>
      <td>As     a result of this standard, <font color="blue">effective</font> for periods beginning after January 1,     2006, we and other companies are required to record a <font color="blue">compensation expense</font>     equal to the <font color="blue">fair value</font> of <font color="blue">each stock option granted</font></td>
    </tr>
    <tr>
      <td>We are currently     assessing our <font color="blue">valuation options allowed</font> in this standard</td>
    </tr>
    <tr>
      <td>This change in     <font color="blue">accounting standards reduces</font> the <font color="blue">attractiveness</font> of <font color="blue">granting <font color="blue">stock options</font></font>     because of the <font color="blue">additional</font> expense associated with these grants, which would     <font color="blue">negatively impact</font> our results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Nevertheless, <font color="blue">stock options</font> are     an <font color="blue">important <font color="blue">employee recruitment</font></font> and retention tool, and we may not be able     to attract and retain <font color="blue">key personnel</font> if we reduce the scope of our employee     <font color="blue">stock option program</font></td>
    </tr>
    <tr>
      <td>Accordingly, <font color="blue">even though</font> we have not quantified the     impact of the <font color="blue">implementation</font> of this standard will have on our financial     condition and results of <font color="blue">operations</font> at this time, the result will have a     negative  impact  on  our <font color="blue">earnings starting with</font> the <font color="blue">accounting period</font>     beginning January 1, 2006</td>
    </tr>
    <tr>
      <td>In addition, the new standard <font color="blue">could negatively</font>     impact our ability to use <font color="blue">stock options</font> as an <font color="blue">employee recruitment</font> and     retention tool in the future</td>
    </tr>
    <tr>
      <td>We have limited <font color="blue">manufacturing</font> experience and have only <font color="blue">manufacture</font>d limited     quantities of <font color="blue">oxygen <font color="blue">implanters</font></font></td>
    </tr>
    <tr>
      <td>To be successful, our <font color="blue">products must</font> be     <font color="blue">manufacture</font>d in commercial quantities, at acceptable costs</td>
    </tr>
    <tr>
      <td>We may not be     able  to  make  the  transition  to  <font color="blue">high volume commercial production</font>     <font color="blue">successfully</font></td>
    </tr>
    <tr>
      <td><font color="blue">Future                                           </font>16     ______________________________________________________________________         production in <font color="blue">commercial quantities may</font> create technical and financial     <font color="blue">challenges</font>  for us</td>
    </tr>
    <tr>
      <td>Any <font color="blue">difficult</font>y or delay in constructing <font color="blue">additional</font>     <font color="blue">implanters</font>, if needed, could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>Our Latest Products Have Not Been Used in Large-Scale Long-Term Production     and They May Not Be Able to Perform at the <font color="blue">Availability Levels Expected </font>for     <font color="blue">Continuous </font>(7 Days per Week / 24 Hours per Day) Operation</td>
    </tr>
    <tr>
      <td><font color="blue">Semiconductor </font>equipment is subject to <font color="blue">stringent mean</font> time <font color="blue">between failure</font>     (MBTF)  and similar quality and <font color="blue">reliability</font> <font color="blue">requirements</font></td>
    </tr>
    <tr>
      <td>Although our     equipment has <font color="blue">previously been used</font> in our own <font color="blue">production environment</font> for     <font color="blue">manufacturing</font> <font color="blue">SIMOX SOI </font>wafers, and has been used in limited <font color="blue">manufacturing</font>     runs  in our <font color="blue">customers site</font>s, as our equipment is exposed to long-term     <font color="blue">extended production processing on</font> an automated basis, previously unknown and     <font color="blue">undetected hardware</font> or <font color="blue">software failures</font> or <font color="blue">combinations thereof may</font> occur</td>
    </tr>
    <tr>
      <td>Such failures could <font color="blue">adversely</font> affect our <font color="blue">relationship with</font> our customers</td>
    </tr>
    <tr>
      <td>We  May Not Be Able to Use All of Our Existing or Future Manufacturing     Capacity at a <font color="blue">Profitable Level</font></td>
    </tr>
    <tr>
      <td>At  times we may have the <font color="blue">capacity</font> to produce more <font color="blue">oxygen implantation</font>     <font color="blue">machines than</font> we have orders for <font color="blue">at such times</font></td>
    </tr>
    <tr>
      <td>During such idle time we     <font color="blue">would continue</font> to be responsible for the fixed costs of our <font color="blue">facility</font> and     maintaining personnel, <font color="blue">which could</font> have a material adverse effect on our     business</td>
    </tr>
    <tr>
      <td>We  believe  we will need to form or maintain <font color="blue">alliances with strategic</font>     partners for the <font color="blue">manufacturing</font>, marketing and <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">may enter into</font> these <font color="blue">strategic alliances</font> to <font color="blue">satisfy customer demand</font> and     to <font color="blue">address possible customer concerns</font> regarding our being a sole source     supplier</td>
    </tr>
    <tr>
      <td>The limited number of <font color="blue">reliable sources</font> of supply other than <font color="blue">Ibis     </font>may  <font color="blue">adversely</font>  affect or delay the integration of SIMOX-SOI wafers in     mainstream commercial <font color="blue"><font color="blue">application</font>s</font></td>
    </tr>
    <tr>
      <td>We may not be successful in maintaining     alliances  or  in  forming  and maintaining other alliances, including     satisfying our <font color="blue">contractual obligations with</font> our <font color="blue">strategic partners</font>, and our     partners  may not <font color="blue">devote adequate resources</font> to <font color="blue">manufacture</font>, market and     distribute these products <font color="blue">successfully</font> or <font color="blue">may attempt</font> to <font color="blue">compete with</font> us</td>
    </tr>
    <tr>
      <td>We May Have Difficulty Obtaining the Materials and Components Needed to     <font color="blue">Produce Our Products</font></td>
    </tr>
    <tr>
      <td><font color="blue">At Least One Major Component Has Only One Source</font></td>
    </tr>
    <tr>
      <td>Ibis <font color="blue">manufacture</font>s its <font color="blue">oxygen <font color="blue">implanters</font></font> from standard <font color="blue">components</font> and from     <font color="blue">components</font> <font color="blue">manufacture</font>d in-house or by other <font color="blue">vendors according</font> to our design     <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Most <font color="blue">raw materials</font> and <font color="blue">components</font> not produced by us are     <font color="blue">available from</font> more <font color="blue">than one supplier</font></td>
    </tr>
    <tr>
      <td>However, certain <font color="blue">raw materials</font>,     <font color="blue">components</font> and <font color="blue">subassemblies</font> are obtained from a limited group of suppliers     and <font color="blue">at least one major</font> component has a sole source</td>
    </tr>
    <tr>
      <td>If we are unable to     obtain <font color="blue">such materials</font> and <font color="blue">components</font> on a <font color="blue">timely basis</font>, or at all, our     ability to complete <font color="blue">orders could</font> be <font color="blue">significant</font>ly delayed and our business     and results from <font color="blue">operations</font> could be <font color="blue">materially</font> and <font color="blue">adversely</font> affected</td>
    </tr>
    <tr>
      <td><font color="blue">Semiconductor </font>equipment is a <font color="blue">growth industry</font> and is very cyclical in nature,     so  if  our  suppliers  experience  an  increase  in <font color="blue">demand from</font> other     <font color="blue">semiconductor</font> equipment <font color="blue"><font color="blue">manufacture</font>rs</font> with much <font color="blue">higher volumes than us</font>, the     lead-time and/or price for some of our <font color="blue">components</font> may increase</td>
    </tr>
    <tr>
      <td>Although we     have sought to reduce our <font color="blue">dependence on</font> these limited <font color="blue">source suppliers</font> and     we have not experienced <font color="blue">significant</font> production delays due to <font color="blue">unavailability</font>     or  delay  in <font color="blue">procurement</font> of component parts or <font color="blue">raw materials</font> to date,     <font color="blue">increased market demand</font> for <font color="blue">materials from</font>, or <font color="blue">disruption</font> or <font color="blue">termination</font> of,     certain of these <font color="blue">sources could</font> occur and such increased demand, <font color="blue">disruption</font>s,     or <font color="blue">termination</font> could have a material adverse effect on our business and     results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our ability to compete <font color="blue">effective</font>ly with other <font color="blue">companies will depend</font>, in     part, on our ability to maintain the <font color="blue">proprietary</font> nature of our <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>Although we have been awarded or have filed <font color="blue"><font color="blue">application</font>s</font> for a number of     patents in the US and foreign countries, those patents may not provide     <font color="blue">meaningful</font> protection, or                                           17     ______________________________________________________________________         pending patents may not be issued</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">competitor</font>s</font> in both the US and     foreign countries, many of which have <font color="blue">substantially</font> greater resources and     have made substantial <font color="blue">investment</font>s in competing <font color="blue">technologies</font>, may have or may     obtain patents that will prevent, limit or interfere with our ability to     make and sell our products or <font color="blue">intentionally</font> infringe on our patents</td>
    </tr>
    <tr>
      <td>The     defense and <font color="blue">prosecution</font> of <font color="blue">patent suits</font> is <font color="blue">both costly</font> and time-consuming,     even if the outcome is favorable to us</td>
    </tr>
    <tr>
      <td>In addition, there is an inherent     <font color="blue">unpredictability</font> regarding obtaining and <font color="blue">enforcing patents</font></td>
    </tr>
    <tr>
      <td>An adverse     outcome in the defense of a <font color="blue">patent suit could</font>:         •                subject us to <font color="blue">significant</font> <font color="blue">liabilities</font> to <font color="blue">third parties</font>,       •                require <font color="blue">disputed rights</font> to be licensed from <font color="blue">third parties</font>,     or       •                require us to <font color="blue">cease selling</font> our products</td>
    </tr>
    <tr>
      <td>We also rely in large part on unpatented <font color="blue">proprietary</font> <font color="blue">technology</font> and others,     including <font color="blue">strategic partners</font>, may independently develop the same or similar     <font color="blue">technology</font> or otherwise obtain access to our <font color="blue">proprietary</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>To     protect our rights in these areas, we currently require all of our employees     to <font color="blue">enter into confidentiality agreements</font></td>
    </tr>
    <tr>
      <td>However, these <font color="blue">agreements may</font> not     provide <font color="blue">meaningful</font> protection for our trade secrets, know-how or other     <font color="blue">proprietary</font>   information  in  the  event  of  any  <font color="blue">unauthorized</font>  use,     <font color="blue">misappropriation</font> or <font color="blue">disclosure</font> of such trade secrets, know-how or other     <font color="blue">proprietary</font> information</td>
    </tr>
    <tr>
      <td>Others may claim that our <font color="blue">technology</font> infringes on their <font color="blue">proprietary</font> rights</td>
    </tr>
    <tr>
      <td>Any <font color="blue">infringement</font> claims, even if <font color="blue">without merit</font>, can be time consuming and     expensive to defend and may divert <font color="blue">management</font>’s attention and resources</td>
    </tr>
    <tr>
      <td>If     successful, they <font color="blue">could also</font> require us to <font color="blue">enter into costly royalty</font> or     <font color="blue">licensing agreements</font></td>
    </tr>
    <tr>
      <td>A successful claim of product <font color="blue">infringement</font> against us     and our <font color="blue">inability</font> to license the infringed or similar <font color="blue">technology</font> could     <font color="blue">adversely</font> affect our business</td>
    </tr>
    <tr>
      <td>If We Do Not Comply With All Applicable Environmental Regulations, We Could     be <font color="blue">Subject to Fines and Other Sanctions</font></td>
    </tr>
    <tr>
      <td>We  are subject to a variety of federal, state and <font color="blue">local environmental</font>     <font color="blue">regulations</font> related to the storage, treatment, discharge or disposal of     <font color="blue">chemicals used</font> in our <font color="blue">operations</font> and to the exposure of our personnel to     <font color="blue">occupational hazards</font></td>
    </tr>
    <tr>
      <td>Although we believe that we have all permits <font color="blue">necessary</font>     to  conduct our business, the failure to <font color="blue">comply with present</font> or future     <font color="blue">regulations</font>  could  result in fines being imposed on us, suspension of     production or a cessation of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">future <font color="blue">activities</font> may</font> result in     our being subject to <font color="blue">additional</font> <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Such <font color="blue">regulations</font> could require     us to acquire <font color="blue">significant</font> equipment or to incur other substantial expenses     to  comply  with <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Our failure to control the use of, or to     <font color="blue">restrict adequately</font> the discharge of, <font color="blue">hazardous substances</font> or properly     control other <font color="blue">occupational hazards</font> could subject us to substantial financial     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td><font color="blue">Our Stock Price </font>is <font color="blue">Highly Volatile</font></td>
    </tr>
    <tr>
      <td>The <font color="blue"><font color="blue">market price</font>s</font> for securities of <font color="blue">high tech companies</font> have <font color="blue">been volatile</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">volatility</font> has <font color="blue">significant</font>ly affected the <font color="blue"><font color="blue">market price</font>s</font> for these     securities for <font color="blue">reasons frequently unrelated</font> to the operating performance of     the <font color="blue">specific companies</font></td>
    </tr>
    <tr>
      <td>These broad market <font color="blue">fluctuations</font> may <font color="blue">adversely</font> affect     the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> for our <font color="blue">common stock</font>     has fluctuated <font color="blue">significant</font>ly</td>
    </tr>
    <tr>
      <td><font color="blue">Since January </font>1, 1999, our stock price has     <font color="blue">fluctuated from</font> a high of dlra135dtta00 to a low of dlra1dtta14</td>
    </tr>
    <tr>
      <td>It is likely that the     <font color="blue">market price</font> of our stock <font color="blue">will continue</font> to fluctuate in the future</td>
    </tr>
    <tr>
      <td><font color="blue">Events     </font>or factors that may have a <font color="blue">significant</font> impact on our business and on the     <font color="blue">market price</font> of our <font color="blue">common stock</font> include the following:         •                  <font color="blue">quarterly <font color="blue">fluctuations</font></font> in operating results,       •                  <font color="blue">difficult</font>y in forecasting future results,       •                   <font color="blue">announcements</font>  by  us  or our present or potential     <font color="blue"><font color="blue">competitor</font>s</font>,       •                  <font color="blue">technological</font> <font color="blue">innovations</font> or new commercial products or     services by us or our <font color="blue"><font color="blue">competitor</font>s</font>,       •                   the  timing of receipt of orders and / or customer     <font color="blue">acceptance</font> from <font color="blue">major customers</font>,       •                  product mix,       •                  product obsolescence,                                           18     ______________________________________________________________________         •                shifts in customer demand,       •                 our  ability  to  <font color="blue">manufacture</font> and ship products on a     cost-<font color="blue">effective</font> and <font color="blue">timely basis</font>,       •                market <font color="blue">acceptance</font> of new and enhanced versions of our     <font color="blue">implanters</font>,       •                the evolving and unpredictable nature of the markets for     the <font color="blue">products incorporating</font> SIMOX-SOI wafers,       •                the amount of research and <font color="blue">development</font> expenses associated     with new or <font color="blue">enhanced products</font> or <font color="blue">implanters</font>       •                the cyclical nature of the <font color="blue">semiconductor</font> industry, and       •                <font color="blue">general market <font color="blue">conditions</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">Concentrated Ownership of Shares </font>by One Shareholder Could Affect the Price     of Our Common Stock</td>
    </tr>
    <tr>
      <td><font color="blue">As of <font color="blue">February </font></font>28, 2006, our <font color="blue">largest known <font color="blue">shareholder</font></font>, Intrinsic Value     Asset Management, Inc</td>
    </tr>
    <tr>
      <td>(“IVAM”) owns 2cmam305cmam389 shares, or <font color="blue">approximately</font>     21dtta5prca of our <font color="blue">outstanding shares</font></td>
    </tr>
    <tr>
      <td>At present, IVAM’s <font color="blue">ownership may</font> have the     effect of delaying, deferring or preventing a change in control of our     company, or <font color="blue">may directly</font> or <font color="blue">indirectly</font> effect a change in control of our     company</td>
    </tr>
    <tr>
      <td>Moreover, the <font color="blue">disposition</font> by IVAM of a substantial amount of its     shares of our <font color="blue">common stock</font> in the <font color="blue">open market could</font> have an <font color="blue">adverse impact</font>     on the market for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Five class <font color="blue">action securities lawsuits</font> have been filed in the United States     District  Court  in the District of <font color="blue">Massachusetts </font>against Ibis and its     President and CEO: Martin Smolowitz v</td>
    </tr>
    <tr>
      <td>Ibis Technology Corporation, et al,     Civ</td>
    </tr>
    <tr>
      <td>); <font color="blue">Weinstein </font>v</td>
    </tr>
    <tr>
      <td>Ibis Technology Corporation, et al, Civ</td>
    </tr>
    <tr>
      <td>); and <font color="blue">Eleanor Pitzer </font>v</td>
    </tr>
    <tr>
      <td>On June 4, 2004, <font color="blue">the Court </font>entered an order     <font color="blue">consolidating</font>  these  actions  under the caption In re Ibis Technology     Securities Litigation, CA 04-10446 <font color="blue">RCL On July </font>6, 2004, a <font color="blue">consolidated</font>     amended class <font color="blue">action complaint</font> was <font color="blue">filed which</font> alleges, among other things,     that  the Company <font color="blue">violated federal securities laws by allegedly</font> making     <font color="blue">misstatements</font> to the <font color="blue">investing public</font> relating to demand for certain <font color="blue">Ibis     </font>products and <font color="blue">intellectual property issues</font> relating to the sale of the i2000     oxygen  implanter</td>
    </tr>
    <tr>
      <td>The plaintiffs are <font color="blue">seeking unspecified damages</font></td>
    </tr>
    <tr>
      <td>On     August 5,  2004, we filed a motion to dismiss the <font color="blue">consolidated</font> amended     <font color="blue">complaint on</font> the grounds, among others, that it failed to state a claim on     which the <font color="blue">relief could</font> be granted</td>
    </tr>
    <tr>
      <td><font color="blue">On September </font>25, 2005 the Magistrate     Judge issued a report and <font color="blue">recommendation</font> that our motion be granted in part     and denied in part</td>
    </tr>
    <tr>
      <td>We and the plaintiffs have <font color="blue">both filed partial <font color="blue">objections</font></font>     to the report and <font color="blue">recommendation</font> with Court, and after briefing of these     <font color="blue">objections</font> is complete, <font color="blue">the Court </font>will determine whether to adopt the report     and  <font color="blue">recommendation</font>  in  whole  or  in part</td>
    </tr>
    <tr>
      <td>While we believe that the     plaintiffs’ allegations are <font color="blue">without merit</font>, and we intend to <font color="blue">vigorously</font>     defend  against  the  suits,  there can be <font color="blue">no guarantee as</font> to how they     <font color="blue">ultimately will</font> be resolved</td>
    </tr>
    <tr>
      <td>In addition, Ibis has <font color="blue">been named as</font> a <font color="blue">nominal defendant</font> in a <font color="blue">shareholder</font>     <font color="blue">derivative action filed</font> in <font color="blue">February </font>2004 against certain of its <font color="blue">directors</font>     and officers: Louis F Matheson, Jr</td>
    </tr>
    <tr>
      <td><font color="blue">Martin J Reid </font>et al, Civ</td>
    </tr>
    <tr>
      <td>The complaint alleges, among other things, that the     alleged <font color="blue">conduct challenged</font> in the <font color="blue">securities cases pending against</font> Ibis in     <font color="blue">Massachusetts </font>(described above) <font color="blue">constitutes</font> a breach of the <font color="blue">defendants</font>’     <font color="blue">fiduciary duties</font> to Ibis</td>
    </tr>
    <tr>
      <td>The <font color="blue">complaint seeks unspecified money damages</font> and     other  <font color="blue">relief ostensibly on behalf</font> of Ibis</td>
    </tr>
    <tr>
      <td>On June 4, 2004, <font color="blue">the Court </font>    entered an order staying this matter pending the entry of a final order on     any <font color="blue">motion filed by</font> the Company to dismiss the <font color="blue">consolidated</font> class action     complaint referenced above</td>
    </tr>
    <tr>
      <td>19     ______________________________________________________________________         <font color="blue">Litigation  </font>may  be time-consuming, expensive and <font color="blue">disruptive</font> to normal     business <font color="blue">operations</font>, and the outcome of <font color="blue">litigation</font> is <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>An <font color="blue">unfavorable resolution</font> of these <font color="blue">litigation</font> matters could have a material     adverse  effect  on  our business, results of <font color="blue">operations</font> and financial     condition</td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> has the authority to approve the issue of up to 2dtta0     million  shares of <font color="blue">preferred stock</font> and to determine the price, rights,     privileges and other terms of these shares</td>
    </tr>
    <tr>
      <td>The board of <font color="blue">directors</font> may     exercise this <font color="blue">authority without</font> the approval of the <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights     of the holders of <font color="blue">common stock</font> may be <font color="blue">adversely</font> affected by the rights of     the holders of any <font color="blue">preferred stock</font> that may be issued in the future</td>
    </tr>
    <tr>
      <td>Our <font color="blue">restated articles</font> of <font color="blue">organization</font>, as amended, and <font color="blue">restated bylaws</font> and     the <font color="blue">Massachusetts </font>Business Corporation Law <font color="blue">contain certain provisions</font> that     may make a third-party acquisition of us <font color="blue">difficult</font>, including:         •                a <font color="blue">classified board</font> of <font color="blue">directors</font>, with three classes of     <font color="blue">directors</font> each serving a staggered three-year term,       •                the ability of the board of <font color="blue">directors</font> to <font color="blue">issue preferred</font>     stock, and       •                a 75prca super-majority <font color="blue">shareholder</font> vote to <font color="blue">amend certain</font>     provisions of our articles of <font color="blue">organization</font> and bylaws</td>
    </tr>
    <tr>
      <td><font color="blue">Limitations </font>on <font color="blue">Effectiveness of Controls</font></td>
    </tr>
    <tr>
      <td>The  Company’s  <font color="blue">management</font>,  including the <font color="blue">Chief Executive Officer </font>and     President and the Chief Financial Officer, does not expect that our internal     <font color="blue">controls will prevent</font> all errors and <font color="blue">intentional misrepresentations</font></td>
    </tr>
    <tr>
      <td>A     control system, no matter how well conceived and operated, can <font color="blue">provide only</font>     reasonable, not absolute, assurance that the <font color="blue">objectives</font> of the control     system are met</td>
    </tr>
    <tr>
      <td>Further, the design of a <font color="blue">control system must reflect</font> the     fact that there are <font color="blue">resource constraints</font>, and the benefits of <font color="blue">controls must</font>     be considered relative to their costs</td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">inherent limitations</font>     in all control systems, no evaluation of controls can <font color="blue">provide absolute</font>     assurance that all <font color="blue">control issues</font>, if any, within the Company have been     detected</td>
    </tr>
    <tr>
      <td>These <font color="blue">inherent limitations</font> include the realities that judgments     in decision-making can be faulty and that <font color="blue">breakdowns</font> can occur because of     <font color="blue">simple error</font> or mistake</td>
    </tr>
    <tr>
      <td>Additionally, controls can be <font color="blue">circumvented by</font> the     individual acts of some persons, by collusion of two or more people, or by     <font color="blue">management</font> override of the control</td>
    </tr>
    <tr>
      <td>The design of any system of controls     also is based in part <font color="blue">upon certain assumptions about</font> the likelihood of     <font color="blue">future events</font>, and no assurance can be given that any <font color="blue">design will</font> succeed in     achieving its stated <font color="blue">goals under</font> all potential future <font color="blue">conditions</font>; over time,     <font color="blue">controls may become</font> inadequate because of changes in <font color="blue">conditions</font>, or the     degree  of <font color="blue">compliance with</font> the policies or <font color="blue">procedures may deteriorate</font></td>
    </tr>
    <tr>
      <td>Because of the <font color="blue">inherent limitations</font> in a cost-<font color="blue">effective</font> control system,     <font color="blue">misstatements</font> due to error or <font color="blue">intentional conduct may</font> occur and not be     detected</td>
    </tr>
    <tr>
      <td><font color="blue">Changing </font>laws, <font color="blue">regulations</font> and standards relating to <font color="blue">corporate governance</font>     and public <font color="blue">disclosure</font>, including the Sarbanes-Oxley Act of 2002 and related     SEC <font color="blue">regulations</font> as well as the <font color="blue">listing standards</font> of the Nasdaq Stock Market,     are creating <font color="blue">uncertainty</font> for <font color="blue">public companies</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">continually evaluate</font> and     monitor <font color="blue">development</font>s with respect to new and <font color="blue">proposed rules</font> and cannot     predict or estimate the amount of the <font color="blue">additional</font> costs we may incur or the     timing of <font color="blue">such costs</font></td>
    </tr>
    <tr>
      <td>These new or changed laws, <font color="blue">regulations</font> and standards     are subject to <font color="blue">varying interpretations</font>, in many <font color="blue">cases due</font> to their lack of     <font color="blue">specificity</font>, and as a result, their <font color="blue">application</font> in <font color="blue">practice may evolve over</font>     time <font color="blue">as new guidance</font> is <font color="blue">provided <font color="blue">by regulatory</font></font> and governing                                                                                   20     ______________________________________________________________________                                                 bodies</td>
    </tr>
    <tr>
      <td>This could result in continuing <font color="blue">uncertainty</font> regarding compliance     matters and <font color="blue">higher costs necessitated by ongoing revisions</font> to <font color="blue">disclosure</font> and     <font color="blue">governance practices</font></td>
    </tr>
    <tr>
      <td>We are committed to maintaining <font color="blue">high standards</font> of     <font color="blue">corporate governance</font> and public <font color="blue">disclosure</font></td>
    </tr>
    <tr>
      <td>As a result, we have invested     resources to comply with evolving laws, <font color="blue">regulations</font> and standards</td>
    </tr>
    <tr>
      <td><font color="blue">This     </font><font color="blue">investment</font> may result in <font color="blue">increased general</font> and <font color="blue">administrative expenses</font> and a     diversion  of  <font color="blue">management</font>  time  and attention from revenue-<font color="blue">generating</font>     <font color="blue">activities</font> to compliance <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>If our efforts to <font color="blue">comply with new</font> or     changed laws, <font color="blue">regulations</font> and <font color="blue">standards differ from</font> the <font color="blue">activities</font> intended     <font color="blue">by regulatory</font> or <font color="blue">governing bodies due</font> to <font color="blue">ambiguities</font> related to practice,     regulatory authorities may initiate legal proceedings against us and we may     be harmed</td>
    </tr>
  </tbody>
</table>